期刊文献+

贝伐单抗结合培美曲塞与顺铂化疗对非小细胞肺癌患者细胞因子及免疫指标的影响

Effect of Bevacizumab combined with Pemetrexed and Cisplatin on Cytokines and Immune Indexes in Patients with Non-small Cell Lung Cancer
原文传递
导出
摘要 目的探讨顺铂、培美曲塞和贝伐单抗联合对非小细胞肺癌患者细胞因子及免疫指标的影响。方法选取2021年1月至2022年5月山东省公共卫生临床中心收治的200例非小细胞肺癌患者作为研究对象,按随机数字表法分为A组与B组,每组100例。A组采用培美曲塞与顺铂治疗,B组在A组基础上加用贝伐单抗,比较两组的治疗效果。结果B组治疗有效率为73.00%,高于A组的58.00%(P<0.05);治疗后,B组血管内皮生长因子A(VEGF-A)、血管内皮生长因子B(VEGF-B)、血管内皮生长因子C(VEGF-C)水平低于A组(P<0.05);治疗后,B组CD4^(+)、CD4^(+)/CD8^(+)高于A组,CD8^(+)、Treg低于A组,差异有统计学意义(P<0.05);B组不良反应发生率为27.00%,高于A组的22.00%,但差异无统计学意义(P>0.05)。结论顺铂、培美曲塞和贝伐单抗联合治疗非小细胞肺癌临床效果显著,有利于病情缓解,改善患者细胞因子水平、机体免疫功能,而且还能使不良反应发生率降低,具有可靠性及安全性。 Objective To explore the effects of combination of cisplatin,pemetrexed and bevacizumab on cytokines and immune indexes in patients with non-small cell lung cancer.Methods A total of 200 patients with non-small cell lung cancer admitted to the Public Health Clinical Center of Shandong Province from January 2021 to May 2022 were selected as the study objects and divided into group A and group B according to random number table method,with 100 patients in each group.Group A was treated with pemetrexed and cisplatin,group B was treated with bevacizumab on the basis of group A,and the therapeutic effect of the two groups was compared.Results The effective rate of group B was 73.00%,which was higher than that of group A(58.00%)(P<0.05).After treatment,the levels of vascular endothelial growth factor A(VEGF-A),VEGF-B(VEGF-B)and VEGF-C(VEGF-C)in group B were lower than those in group A(P<0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)in group B were higher than those in group A,and CD8^(+)and Treg were lower than those in group A,the difference was statistically significant(P<0.05).The incidence of adverse reactions in group B was 27.00%,higher than that in group A(22.00%),but the difference was not statistically significant(P>0.05).Conclusion The combination of cisplatin,pemetrexed and bevacizumab in the treatment of non-small cell lung cancer has significant clinical effect,which is conducive to the remission of the disease,improving the cytokine level and immune function of patients,and can also reduce the incidence of adverse reactions,which is reliable and safe.
作者 孙婷 SUN Ting(Static Distribution Center,Shandong Public Health Clinical Center,Jinan 250013,China)
出处 《中国药物经济学》 2024年第3期83-86,共4页 China Journal of Pharmaceutical Economics
关键词 非小细胞肺癌 培美曲塞 贝伐单抗 顺铂 Non-small cell lung cancer Pemetrexed Bevacizumab Cisplatin
  • 相关文献

参考文献14

二级参考文献87

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部